Prevention begins with Protection

BVD has been estimated to cost the New Zealand cattle industry around $150 million a year.

LIC Data shows the prevalance of BVD in dairy herds is high¹

• 63% of dairy herds had a milk antibody level of >0.75
• 13% of herds contained milking PI animals.

The situation in beef herds in New Zealand is similar.

• In a comparative study² of 94 low and high fertility beef herds, 65% were actively infected with BVD
• A more recent study³ of 43 beef herds showed 58% had evidence of recent BVD infection.

Bovilis BVD is the only BVD vaccine with a 12 month fetal protection claim*

*Bovilis BVD provides 6 months fetal protection following the initial vaccination series (sensitiser and booster), and 12 months fetal protection following a third dose.

The key to BVD control is protecting the fetus to prevent PI calves being formed.

Bovilis BVD has a flexible primary dosing interval of 4 weeks to 6 months between the initial sensitiser and booster shots.

This extended vaccination interval allows farmers the convenience of aligning their vaccination schedule with other planned management practices.

Bovilis BVD is made with strain C86, a Type 1a BVD virus which is the predominant subtype in NZ⁵.

• Australian isolates are predominantly subtype 1c⁶
• The C86 strain and adjuvant in Bovilis BVD are highly immunogenic^7,8
• Bovilis BVD provides protection against diverse Type 1&2 BVD viruses, as well as Border Disease viruses^7,8

Vaccination with Bovilis BVD improves reproductive performance in herds with active BVD infection⁹

Vaccinating with Bovilis BVD doesn't cause a drop in milk production.

New Zealand dairy herds are vaccinated when milk production is near its peak, so its important that a vaccine has no effect on milk production.

A field study has demonstrated no observable difference between vaccinated and control animals following vaccination, and no effect on average milk yields.¹⁰

Bovilis BVD provides 12 months duration of immunity for transient infection.¹¹

While transiently infected animals are not the main source of BVD spread within a herd it is the most frequent infection type and the cost of lost production from a transiently infected animal is significant.

Bovilis BVD is formulated for safety in pregnant cows.

In breeding cattle it is good practice to administer the booster vaccination no less than, but close to 4 weeks before the planned start of mating to ensure fetal protection in early gestation. Bovilis BVD is safe for use in pregnant cows which provides confidence in situations when there is an extended mating period. If any cattle are pregnant at the time of vaccination there will be no adverse effects for the cow or her unborn calf.

* Following a third dose (annual vaccination) Bovilis BVD provides 12 months fetal protection.
1. Voges, H. and Hill, F. BVD Steering Committee Roadshow 2014
2. Heuer, C. et al. (2008). Effect of reproductive pathogens on pregnancy rates in beef herds. Proc. 38th Sem. Soc. Sheep and Beef Cattle Vets. NZVA; 141-147
3. Cuttance, W & Cuttance. (2014) E. Analysis of individual farm investigations into bovine viral diarrhoea in beef herds in the North Island of New Zealand. NZ Vet J. Nov; 62(6): 338-42
4. Weir A. PhD work submitted June 2016 
5. Horner GW et al. (2000) Typing of New Zealand strains of pestivirus. Surveillance 27(3):16
6. Mahony et al. (2005) Genetic analysis of bovine viral diarrhoea viruses from Australia. Veterinary Microbiology 106 1-6
7. Patel, J.R. et al. (2005) Variation in immunogenicity of ruminant pestiviruses as determined by the neutralisation assay, The Veterinary Journal, Vol 169, 468-472.
8. Makoschey, B et al. (2001) An inactivated bovine viral diarrhoea virus (BVDV) type 1 vaccine affords clinical protection against BVD type 2.
9. Mawhinney, I., (2005) Vaccination with Bovilis BVD-MD improves fertility in dairy herds under field conditions. Tierärztliche Umschau 60(9):501-502
10. MSD Data on file
11. Munoz Bielsa, J. et al. Evaluation of the level of protection afforded by a BVD inactivated vaccine (C-86 strain), 12 months after vaccination. Journees Nationales des GTV, Nantes, 2005, 903

Since its launch in 2011, Bovilis MH+IBR has been used extensively in the Australian cattle industry where it has been shown to be extremely effective at reducing levels of respiratory disease morbidity and mortality.

In a large Australian feedlot trial¹, cattle vaccinated with 2 doses of Bovilis MH+IBR had significantly lower morbidity and mortality rates due to BRD than control cattle vaccinated with other vaccines.

Click to enlarge

Bovilis MH+IBR has a flexible primary dosing interval of 2 weeks to 9 months between the initial sensitiser and booster shots.

This extended vaccination interval allows farmers the convenience of aligning their vaccination schedule with other planned management practices.

1. Bovilis MH+IBR Field Trials: 2009:001. ISPAH Data on file. Rhinogard™ , APVMA: 49679, Registered to Zoetis Australia Pty Limited
2. The MSD Veterinary Manual (9th edition)(2008). www.msdvetmanual.com
3. MLA, Controlling BRD in feedlot cattle, FL06, 2001
4. Bovilis MH+IBR Field Trials: 20019:001. MSD Data on file

Rotavec Corona is the gold-standard for the prevention of scours.

Calves are born without antibodies to fight infection. They rely completely on high-quality colostrum for protection against scours-causing pathogens.

It is critical that calves receive enough of the right antibodies in colostrum, and then in transition milk, to reduce their risk of scours.

Rotavec Corona significantly elevates neutralising antibodies in colostrum and milk for at least 28 days post-calving³

 

Research shows Rotavec Corona vaccination boosts levels of both G6 and G10 antibodies.⁴

Cross-protection

Cows vaccinated with a single serotype produce antibodies to all serotypes to which they have had prior exposure. This response has been demonstrated by numerous researchers^5,6,7 and is also observed with other viruses that have marked antigenic variability such as influenza.

Faeces from calves fed colostrum from Rotavec Corona vaccinated cows contain less virus. This results in reduced environmental contamination and less likelihood of virus spread to uninfected calves.⁴